Prevention With Healsea in Adults Against Respiratory Infection Study

Upper respiratory tract infections (URTIs) and sino-nasal symptoms are very frequent.

Human rhinovirus (more than 100 serotypes) is the most common cause, accounting up to 50% viral rhinitis episodes in children and adults. These episodes can last up to 7-10 days and are usually self-limited. Prevalence of acute rhinosinusitis varies with season (higher in the fall and winter months) and climatic variations and increases with a damp environment and air pollution. The incidence of acute rhinitis/rhinosinusitis is very high, estimated to occur from 2 to 5 times per year in the average adult.

Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds and rhinitis. The clinical performance of Healsea® Children is supported by the sea water solution and Symbiofilm™. The exact mechanisms by which nasal irrigation works are not known. However, most of the experts agree that it is primarily a mechanical intervention leading to direct cleaning of the nasal mucosa.

The other component of Healsea® Children, Symbiofilm™ is an exopolymeric composition with emulsifying/surfactant properties which enhance the cleansing and moistening of nasal mucosa. Furthermore, a prophylactic activity of Symbiofilm™ against infection by viruses involved in upper respiratory infections i.e., Adenovirus, Rhinovirus, Flu virus and OC 43 Coronavirus has been demonstrated in vitro on human nasal epithelial cells (HNEpC). The antiviral prophylactic activity of Symbiofilm™ is suggested to rely on its physiochemical properties that, by coating the surface of epithelial cells, hinders the viral entry process, thus explaining the reduced viral adsorption and the subsequent reduced onset of infection.

By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections with nasal symptoms not only in children (HEALSPIC study, NCT06582589) but also in the adult population.

The aim of this two arms prospective randomized open-labelled pre-market clinical investigation, is to establish clinical benefits and clinical safety of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy adults during 3 treatment periods of 28 days (one puff in each ostril twice daily) interspersed by 2 wash-out periods of 10 days when compared to adults not taking Healsea® Children.

198 children will be randomised in the study, 99 in the Healsea® Children group and 99 in the non-treated group.

The subjects will be asked to immediately call the investigator in case of nasal symptoms and complication of respiratory infection they may have during the study.

Two study visits (Visit 1, Screening/Randomisation at Day 1 and Visit 2, End of study visit at Day 106 up to Day 116) and 3 telephone calls (telephone call 1 TC1 at Day15 ±3 days, TC2 at Day 55 ±3 days and TC3 at Day 95±3days) are scheduled. The subjects will also complete an electronic diary to report nasal symptoms, device deficiencies, and adverse events other than upper respiratory tracts infections from D2 up to end of study (Day 106 up to Day 116).

The duration of patient's participation is up to 116 days.

Inclusion criteria

Subjects will be enrolled if they meet all the following criteria:

• Healthy Male/Female subjects ≥18 years
• No respiratory tract infection within 15 days before trial entry and at trial entry
• Willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the information consent form
• Availability of a smartphone throughout the study and an internet connection.

Exclusion criteria

Subjects will not be enrolled if one of the following criteria is present:

• Known hypersensitivity/allergy to any component of the test device
• Subject with COPD, severe asthma, perennial allergy, immunodeficiency or cystic fibrosis
• Body temperature ≥ 37.8°C
• Medical history or any current disease that is considered by the investigator as a reason for non-inclusion
• Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps
• Antibiotic (systemic or per nasal route) or antivirals (systemic) intake within 2 weeks before screening
• Systemic or local corticosteroids (nasal route or inhalation) within 4 weeks before screening
• Antihistamines intake for allergy when treatment was started from less than 4 weeks before screening
• Vaccination against flu or COVID-19 within 6 months before screening
• Chronic decongestant use within 2 weeks before screening
• Bacterial lysates, or immunostimulants (food supplements excluded) used for prevention of infection within the 6 months before the screening
• Prebiotics, probiotics used for prevention of infection within 6 months before the screening
• Pregnant/Lactating female or of childbearing potential without hormonal contraception or intrauterine device or double barrier method.